雷珠单抗玻璃体腔内注射联合激光在糖尿病性黄斑水肿中的应用

合集下载

康柏西普玻璃体腔注射联合全视网膜光凝术治疗合并黄斑水肿的重度非增殖性糖尿病视网膜病变

康柏西普玻璃体腔注射联合全视网膜光凝术治疗合并黄斑水肿的重度非增殖性糖尿病视网膜病变

山东医药2020年第60卷第30期康柏西普玻璃体腔注射联合全视网膜光凝术治疗合并黄斑水肿的重度非增殖性糖尿病视网膜病变刘矫连,左慧懿,衷昕广西医科大学第一附属医院,南宁530021摘要:目的康柏西普观察玻璃体腔注射联合全视网膜光凝术(PRP)治疗重度非增殖性糖尿病视网膜病变(NPDR)患者黄斑水肿的效果。

方法46例合并黄斑水肿的NPDR患者,分为对照组20例、观察组26例。

两组均采用PRP治疗,且1个月内完成2~3次PRP治疗。

观察组在在首次PRP治疗前48h时玻璃体腔注射康柏西普(0.5mg/0.05mL)治疗,1次/月琏续3次。

分别于治疗前及治疗1、2、3个月时观察两组最佳矫正视力(BCVA)值及黄斑中心凹厚度(CMT)o观察组注射康柏西普治疗前、治疗24h时检测眼压并观察眼部并发症发生情况。

结果治疗前及治疗第1、2、3个月时观察组BCVA分别为1.10(1.00,1.20)90(0.80,1.10) ,.80(0.7,0.90、、0.70(0.50,0.80)患MT分别为413.0(378.0,435.0)355.5(321.0,408.0)309.5(286.0,334.0)264.5(248.0,285.0^m;治疗前及治疗第1、2、3个月时对照组BCVA分别为1.10(1.00,1.20),.10(1.00,1.20)00(0.90,1.10),.00(0.90,1.10)CMT分别为417.5(353.0,433.5)、412.0(357.0,438.5)、412.0(354.5,434.0),11.0(353.0,430.0)|±m。

与治疗前比较,对照组治疗2、3个月时BCVA增加,观察组治疗1、2、3个月时BCVA增加、CMT降低(P均<0.05);与对照组比较,观察组治疗1、2、3个月时BCVA增加、CMT降低(P均<0.05);与治疗2个月时比较,观察组治疗3个月时BCVA增加、CMT降低(P<0.05)o观察组3次注药前后眼压变化均无统计学意义。

糖尿病性黄斑水肿的早期诊断与治疗

糖尿病性黄斑水肿的早期诊断与治疗

糖尿病性黄斑水肿的早期诊断与治疗季玲;陈婷妍;梁勇【期刊名称】《国际眼科杂志》【年(卷),期】2014(14)10【摘要】Diabetic retinopathy ( DR ) is one of the main blinding eye diseases for people over the age of 50, and diabetic macular edema ( DME) is the leading cause of vision loss is DR patients. The early diagnosis and early treatment is important. As OCT and FFA, mfERG, especially the retinal thickness, volume, retinal edema index quantitative indicators such as objective evaluation of macular edema, embodies the new progress of retinal imaging technology in recent years. OCT is a non -contact clinical application in recent years, noninvasive, high resolution of ophthalmic imaging examination, can do it on retinal ultrastructure observation and quantitative analysis, and the technology is relatively mature, become a routine inspection diagnosis of macular edema. Laser photocoagulation, intravitreous injection with Ranibizumab and vitrectomy is nowadays the important means for the treatment of intractable macular edema.%糖尿病性视网膜病变( diabetic retinopathy,DR)是50岁以上人群主要致盲眼病之一,而糖尿病性黄斑水肿( diabetic maeular edema, DME)则是DR患者视力下降的首要原因。

玻璃体内注射曲安奈德联合激光光凝治疗糖尿病性黄斑水肿的疗效

玻璃体内注射曲安奈德联合激光光凝治疗糖尿病性黄斑水肿的疗效

玻璃体内注射曲安奈德联合激光光凝治疗糖尿病性黄斑水肿的疗效杨海燕【期刊名称】《中国医学创新》【年(卷),期】2012(009)022【摘要】目的:观察玻璃体内注射曲安奈德联合激光光凝治疗糖尿病性黄斑水肿的临床疗效及安全性.方法:对笔者所在医院2008年5月-2010年7月确诊为糖尿病性黄斑水肿的50例(50眼)患者.采用曲安奈德4 mg玻璃体内注射,1周后联合黄斑部格栅样光凝治疗.对比观察治疗前和治疗后1周、1个月及3个月最佳矫正视力及黄斑水肿的改善情况.结果:入选的50例(50眼)患者视力均有不同程度提高,术前视力(0.10±0.08),术后1、3个月矫正视力分别为(0.22±0.15)和(0.29±0.17),眼底荧光血管造影(FFA)及光学相干断层扫描(OCT)显示黄斑水肿明显消退或减轻(P<0.01).未见眼内感染、视网膜脱落、玻璃体出血等并发症.结论:玻璃体内注射曲安奈德联合激光光凝治疗糖尿病性黄斑水肿可以安全有效地提高视力,减轻黄斑水肿.【总页数】2页(P32-33)【作者】杨海燕【作者单位】河南省周口市第三人民医院,河南,周口,466001【正文语种】中文【相关文献】1.玻璃体内注射贝伐单抗和贝伐单抗/曲安奈德联合用药治疗糖尿病性黄斑水肿疗效及安全性差异的荟萃分析 [J], 麻南;李丹;高付林;胡莲娜2.曲安奈德玻璃体内注射联合格栅样光凝治疗糖尿病性黄斑水肿的疗效分析 [J], 曹慧民3.玻璃体内注射曲安奈德联合玻璃体切除术治疗糖尿病性黄斑水肿的临床疗效 [J], 张荟;刘洋4.玻璃体内注射曲安奈德联合玻璃体切除术治疗糖尿病性黄斑水肿的临床疗效 [J], 张荟;刘洋5.康柏西普玻璃体内注射联合视网膜激光光凝术治疗糖尿病性黄斑水肿的疗效观察[J], 李维欣;谢桂丽;孙晓敏;王宇鹰因版权原因,仅展示原文概要,查看原文内容请购买。

雷珠单抗球内注药对糖尿病视网膜病变患者临床效果的影响

雷珠单抗球内注药对糖尿病视网膜病变患者临床效果的影响

世界最新医学信息文摘 2021年 第21卷 第14期193投稿邮箱:zuixinyixue@·药物与临床·雷珠单抗球内注药对糖尿病视网膜病变患者临床效果的影响王星力,张勇,柳维艳(沈阳市第四人民医院 眼科,辽宁 沈阳 110031)0 引言糖尿病为临床常见疾病,临床数据表明,随肥胖人数越来越多,老龄化现象越来越明显,该病发病率逐年上升。

糖尿病患者易伴发微血管并发症,较为常见的为视网膜病变[1]。

部分学者表明,适当控制血脂、血糖与血压可减缓糖尿病视网膜病变进展,但尽管部分患者按医嘱合理控制血压、血糖,仍无法对视网膜病变进展阻止[2]。

临床选用雷珠单抗球内注药治疗效果理想,该研究围绕雷珠单抗球内注药对糖尿病视网膜病变患者临床效果的影响探究,希望改善血糖水平,提高视力,现将有关内容做如下报告。

1 资料与方法1.1 一般资料。

选取2019年3月至2020年10月沈阳市第四人民医院眼科收治的268例糖尿病视网膜病变患者。

将患者随机分为两组,研究组(n =134),男75例,女59例,年龄18~72岁,平均(63.2±1.2)岁;对照组(n =134),男74例,女60例,年龄18~72岁,平均(63.5±1.1)岁。

该研究患者一般资料完整,可配合临床研究,肝肾功能正常。

医院伦理会审批该研究,患者了解该研究相关内容,资料有对比(P>0.05)。

1.2 方法。

①对照组给予雷珠单抗注射治疗,将0.5 mg 雷珠单抗注射于玻璃体腔内,对患者进行表面麻醉,消毒完成后,铺巾。

选择颞上方角巩膜后3.5厘米位置进针,完成注射后涂抹妥布霉素地塞米松眼膏。

②研究组应用X 眼底激光治疗治疗,应用眼底激光治疗仪进行全视网膜光凝处理,保证光斑均匀分布,曝光值为0.2 s ,选择1个光斑直径的光斑间距。

共进行4次光凝操作,对合并水肿或黄斑患者,应给予适量黄斑区格珊样光凝, 共300个光凝点。

曲安奈德联合雷珠单抗治疗对糖尿病性黄斑水肿患者血清VEGF、IL-6、IL-8水平的影响

曲安奈德联合雷珠单抗治疗对糖尿病性黄斑水肿患者血清VEGF、IL-6、IL-8水平的影响

曲安奈德联合雷珠单抗治疗对糖尿病性黄斑水肿患者血清VEGF、IL-6、IL-8水平的影响姬明利;赵奎卿【期刊名称】《中国中医眼科杂志》【年(卷),期】2017(27)6【摘要】目的探讨曲安奈德联合雷珠单抗玻璃体腔注射对糖尿病性黄斑水肿(DME)的治疗效果,以及对患者血清VEGF、IL-6、IL-8水平的影响.方法前瞻性临床对照研究.研究对象为2015年1月-2016年12月在我院确诊为DME的患者166例(235只眼),随机分为两组.A组83例(116只眼),采用玻璃体腔注射雷珠单抗,B组83例(119只眼)采用曲安奈德与雷珠单抗联合注射,均每4周注射1次,共注射3次.治疗前及完成最后一次注射后4周检测两组患者血清血管内皮生长因子(VEGF)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)水平,光学相干断层扫描(OCT)测量黄斑中心视网膜厚度.治疗完毕后对所有患者随访6个月,统计并发症发生情况.结果 1.炎症细胞因子水平:治疗前A组血清VEGF、IL-6、IL-8分别为(432.87±98.24) ng/L,(75.12±8.32) ng/L,(62.34±7.12) ng/L,B组分别为(433.05 ±98.74) ng/L,(74.68 ±8.45) ng/L,(63.08±7.25) ng/L,治疗后A组VEGF、IL-6、IL-8分别为(156.31±68.15) ng/L,(54.85±8.66) ng/L,(43.28±7.56)ng/L,B组分别为(102.50±68.34) ng/L,(52.75±8.35) ng/L,(41.34±7.85) ng/L.治疗前两组各指标水平无明显差异(P>0.05),治疗后各指标数值均较治疗前下降(P<0.05),B组治疗后的血清VEGF明显低于A组(P<0.05),IL-6、IL-8水平与A组相当(P>0.05).2.黄斑中心凹视网膜厚度:治疗前A、B组的黄斑中心视网膜厚度分别为(536.15±86.28)μm,(529.14±84.57) μm,治疗后的结果分别为(386.67±84.11)μm,(321.08±85.16) μm.治疗前两组黄斑中心视网膜厚度接近(P>0.05),治疗后两组数值均较治疗前降低(P<0.05),B组的数值低于A组(P<0.05).3.并发症:A组眼内炎2只眼(1.72%),眼压升高0只眼(0.00%),晶状体混浊加重1只眼(0.86%),出血4只眼(3.45%),总计7只眼(6.03%),B组相应的眼数分别为1只眼(0.84%),5只眼(4.20%),2只眼(1.68%),2只眼(1.68%),总计10只眼(8.40%).组间差异均无统计学意义(P>0.05).结论与单独玻璃体腔注射雷珠单抗相比,联合应用曲安奈德对DME 的治疗效果更好,并能降低血清VEGF、IL-6、IL-8水平,其安全性总体上与单纯应用雷珠单抗相当,可以根据患者的个体情况选择使用.%OBJECTIVE To investigate the therapeutic effect of intravitreal triamcinolone acetonide combined with rezumab on diabetic macular edema (DME) and its impact on serum levels of vascular endothelial growth factor (VEGF),interleukin-6 (IL-6) and interleukin-8 (IL-8).METHODS It was a prospective controlled clinical study.The subjects were 166 patients (235 eyes) diagnosed as DME in our hospital from January of 2015 to December of 2016,which were randomly divided into two groups.In group A,83 cases (116 eyes) were treated by intravitreal injection of rezumab,and 83 cases (119 eyes) in group B were injected with triamcinolone acetonide combined with rezumab.They were injected 1 times every 4 weeks,3 times in a row.Serum levels of VEGF,IL-6 and IL-8 in two groups were detected before the treatment and 4 weeks after the last injection,while the central retinal thickness was measured by optical coherence tomography (OCT).After the treatment,all patients were followed up for 6 months,and the incidence of complications was statistically analyzed.RESULTS 1.The level of inflammatory cell factor:Before intervention,the serum level of VEGF,IL-6,IL-8 in group A were432.87+98.24ng/L,75.12+8.32ng/L,62.34+7.12ng/L;These parameters in B group were 433.05 +98.74ng/L,74.68 +8.45ng/L,63.08 +7.25ng/L;After treatment,VEGF,IL-6 and IL-8 in group A were156.31+68.15ng/L,54.85+8.66ng/L,43.28+7.56ng/L;These indexes in B group were 102.50+68.34ng/L,52.75+8.35ng/L,41.34+7.85ng/L.Before treatment,there were no significant differences in each index level between the two group (P>0.05).After treatment,the result of each index were all decreased significantly (P<0.05).Serum VEGF in group B was significantly lower than it in group A (P<0.05),IL-6 and IL-8 level were similar to counterparts in A group (P>0.05).2.macular central retinal thickness:Before treatment,the macular central retinal thickness in group A and group B was 536.15+86.28μm and 529.14+84.57μm respectively,and the re sults after treatment were 386.67 +84.11μm,321.08 +85.16μm.Before treatment,the macular central retinal thickness of the two groups was close (P>0.05).After treatment,the values of two groups were both dropped significantly (P<0.05),and the result in group B were lower than counterpart in group A (P<0.05)plications:In group A,7 eyes (8.43%) suffered complications,specifically,2 eyes of endophthalmitis (2.41%),0 eyes of increased intraocular pressure (0%),1 eye of increased lens opacity (0.86%),4 eyes of hemorrhage(4.82%);In group B,complications happened in 10 eyes (12.05%),as 1 eyes of endophthalmitis (1.2%) respectively,5 eyes of increased intraocular pressure (6.03%),2 eyes of increased lens opacity and hemorrhage respectively(2.41%).There was no significant difference between groups (P>0.05).CONCLUSIONS Compared with the single use ofintravitreal ranibizumab injection,combined application of triamcinolone acetonide and ranibizumab injection enjoyed better effects on DME,in addition,it decreased the level of VEGF,IL-6,IL-8 and as safe as ranibizumab alone which meant it was a reliable choose for patients with indications.【总页数】4页(P380-383)【作者】姬明利;赵奎卿【作者单位】西安医学院第二附属医院眼科,西安 710038;延安大学附属医院眼科,延安 716000【正文语种】中文【中图分类】R774.5【相关文献】1.雷珠单抗对新生血管性青光眼患者血清、房水IL-6及VEGF水平的影响 [J], 张怡;蒋姝乐;柳婷;杜尔罡2.小梁切除术联合康柏西普或雷珠单抗治疗对NVG患者视力、眼压及血清IP-10、TNF-α、VEGF水平的影响 [J], 龚一波;岳建中3.曲安奈德联合雷珠单抗治疗老年性黄斑变性的效果及对患者炎性因子水平的影响[J], 郭春玲4.雷珠单抗康柏西普玻璃体注射联合AGV治疗新生血管性青光眼的效果及对房水VEGF IL-6水平的影响 [J], 王茜;赵晓霞;吴娟;李海青;秦小萍5.雷珠单抗联合微脉冲激光治疗糖尿病性黄斑水肿的效果及对患者血清PEDF、VEGF水平的影响 [J], 陈洪涛;罗睿强因版权原因,仅展示原文概要,查看原文内容请购买。

抗VEGF药物联合激光光凝治疗糖尿病性黄斑水肿的临床效果观察

抗VEGF药物联合激光光凝治疗糖尿病性黄斑水肿的临床效果观察

抗VEGF药物联合激光光凝治疗糖尿病性黄斑水肿的临床效果观察刘宏真【摘要】目的观察抗血管内皮生长因子(Vascular Endothelial Growth Factor,VEGF)药物联合激光光凝治疗糖尿病性黄斑水肿(Diabetic Macular Edema,DME)的临床效果.方法将2016年2月~2017年1月治疗的106例DME患者作为研究对象,将入选者依据随机数表法分为两组,均53例.对照组实施激光光凝治疗,观察组则加以康柏西普治疗.观察两组临床疗效、视功能、黄斑中心厚度及并发症等.结果两组临床疗效对比,对照组低于观察组,差异有统计学意义(P<0.05);治疗前两组黄斑中心视网膜厚度(Macular Central Retinal Thickness,CMT)、最佳矫正视力(Best-Corrected Visual Acuity,BCVA)相比,差异无统计学意义(P>0.05);治疗后观察组不同时刻CMT、BCVA测定值均优于对照组,差异有统计学意义(P<0.05);两组并发症发生率相比,差异无统计学意义(P>0.05).结论康柏西普与激光光凝联合治疗DME安全高效,有助于改善黄斑水肿程度与水肿区视网膜厚度,促进患者视功能恢复.【期刊名称】《现代诊断与治疗》【年(卷),期】2018(029)002【总页数】3页(P187-189)【关键词】糖尿病性黄斑水肿;抗VEGF药物;激光光凝;临床疗效;视功能【作者】刘宏真【作者单位】南阳市眼科医院眼科,河南南阳 473000【正文语种】中文【中图分类】R587.2;R774.5糖尿病性黄斑水肿(Diabetic Macular Edema,DME)为一种因糖尿病而引发的视网膜微血管病症,属于糖尿病较为常见并发症[1]。

DME可增加机体内血管通透性,导致细胞外液渗漏、积聚,是造成DME患者视力下降甚至失明的常见原因,对患者视功能与身心健康威胁较大[2]。

玻璃体腔注射雷珠单抗治疗CRVO继发黄斑水肿的有效性和安全性

玻璃体腔注射雷珠单抗治疗CRVO继发黄斑水肿的有效性和安全性翟改霞;姜涛;赵善瑶;王文营;王云霄【摘要】AIM:To observe the efficacy and safety of intravitreal injection of Ranibizumab in the treatment of macular edema secondary to central retinal vein occlusion ( CRVO) . <br> METHODS:According to the standard, 24 patients with macular edema secondary to CRVO were double-blind randomized to groupⅠand groupII. They were aged 30~70 years old, average (51. 58±10. 32) years. Patients of groupⅠ were treated with intravitreal injection of 0. 5mg ranibizumab monthly for the first three months and given compound thrombosis capsule. Compared with groupⅠ, patients of group II were only given compound thrombosis capsule. Subjects of two groups use PRN ( Pro re nata ) therapy with ranibizumab from the third month. No significant difference was found between the two groups in the best-corrected visual acuity ( BCVA ) and central retinal thickness ( CRT ) before the treatment (P>0. 05). BCVA, CRT, laboratory results and ocular and systemic adverse reactions of the two groups during treatment were conducted and statistically analyzed. <br> RESULTS: BCVA of group Ⅰ was 52. 67±1. 78 before treatment, and BCVA were respectively 63. 67±1. 61, 66. 25±1. 60, 69. 58±1. 68, 70. 75±5. 22, 65. 58±4. 34, 68. 92±3. 4, 70.17±3. 7 at 1wk, 1, 2, 3, 4, 6, and 12mo aftertreatment&nbsp;with significant difference compared with before injections (P<0. 05). CRT of group Ⅰ was 539. 00±10. 94μm before thetreatment, and that were respectively 326. 67±20. 83, 264. 58±17. 11, 232. 00±13. 04, 231. 25±78. 68, 316. 00±172.48, 218. 00±105. 25, 220. 58±33. 43μm at 1wk, 1, 2, 3, 4, 6, and 12mo after treatment with significant difference compared with before injections ( P< 0. 05 ). BCVA of group II was 52. 25±2. 83 and CRT was 539. 92±12. 21μm, BCVA of group II was 57. 08±3. 12μm 3mo after treatment and significant difference was found compared with group玉3mo after treatment (P<0. 05). CRT of group II was 497. 92 ± 11.91μm 3mo after treatment and significant difference was found compared with group Ⅰ 3mo after treatment ( P < 0. 05 ). Ocular and systemic obviously adverse reactions were not found during treatment. <br> CONCLUSION: Intravitreal injection of ranibizumab contributes to relieving macular edema, improving visual acuity and reducing fluorescence leakage of macular area in short - term. But patients need repeated injection. Ranibizumab is effectiveness and safety in the treatment of macular secondary to CRVO.%目的:观察雷珠单抗对视网膜中央静脉阻塞( central retinal vein occlusion,CRVO )继发黄斑水肿治疗的有效性和安全性。

全视网膜光凝联合雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的疗效及费用比较

全视网膜光凝联合雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的疗效及费用比较潘竹娟;张志辉;樊飞红;郑晓柯;齐文娟【摘要】目的:比较分析全视网膜光凝联合雷珠单抗与曲安奈德(TA)玻璃体腔注射治疗糖尿病黄斑水肿的疗效及医疗费用.方法:收集我院糖尿病视网膜病变伴黄斑水肿患者48例48眼.所有患者行全视网膜激光光凝后随机分为两组.雷珠单抗组:玻璃体腔注射雷珠单抗0.5mg,4wk 1次.共3次.TA组:注射曲安奈德4mg/0.1mL.治疗12wk后若黄斑中心凹视网膜厚度(CMT)≥400μm,则再次注射各组对应药物.随访6mo,对比观察两组患者治疗前及注射药物后的最佳矫正视力(BCVA)、CMT、眼压及相关治疗费用.结果:两组患者BCVA和CMT均无显著统计学差异(P>0.05),不同测量时间点BCVA和CMT具有显著统计学差异,不同治疗方法和时间点BCVA及CMT均存在交互作用(P<0.05).除了TA组注药后1wk时BCVA较治疗前无明显提高(P=0.33),其余各时间点两组BCVA均较治疗前提高(P<0.05).治疗12、16wk雷珠单抗组BCVA提高较 TA 组明显,两组差异有统计学意义(P=0.03、0.045).雷珠单抗组及TA组CMT注药后较注药前均有降低(P<0.05).注射后1wk 两组之间CMT差异有统计学意义(P<0.01).除了1例患者需使用降眼压药物,其余两组患者眼压均在正常范围内.治疗12wk内本研究相关诊疗平均费用雷珠单抗组患者为38736元,TA 组为5790元.治疗24wk 两组平均费用分别为42564元及7053元.结论:短期内全视网膜光凝联合雷珠单抗与曲安奈德玻璃体腔注射均能有效控制DME,两组治疗方法无显著差异,但全视网膜激光联合玻璃体腔注射曲安奈德治疗DME更经济.%·AIM: To compare clinical effects and cost of panretinal photocoagulation (PRP) combined with Ranibizumab or triamcinolone acetonide (TA) for diabetic macular edema(DME). ·METHODS: Forty-eight patients (48 eyes) with DME and diabetic retinopathy ( DR) receiving PRP were randomly assigned to two groups, which were respectively intravitreally injected ranibizumab (0. 5mg) and TA (4mg). Ranibizumab (0.5mg) was intravitreal injected every 4wk for 3 times. The effects of injection for DME were evaluated using best-corrected visual acuity (BCVA ), central macular thickness ( CMT ) and intraocular pressure (IOP). During the follow-up, other injections were performed to eyes which had CMT greater than 400μ m. The medical costs were calculated at 12wk and 24wk.·RESULTS: BCVA and CMT between 2 groups were not significantly different (P>0.05); BCVA and CMT among different time points were significantly different(P<0.05);the treatments and the time points had significant interaction on BCVA (P<0.05). BCVA was improved in two groups at all the time after injection(P<0.05),except 1wk after injection of TA (P=0.33). There was significant difference between the two groups at 12wk and 16wk on BCVA and that injected with ranibizumab was better (P=0.03,0.045). CMT decreased in two groups at all the time after injection (P<0.05). There was significant difference only between the two groups at 1wk (P< 0. 01). All intraocular pressures were in the normal range, except one needed ocular hypotensive agents. The medical costs (yuan) of the ranibizumab group in 12wk and 24wk were 38 736 and 42 564,which of the TA group were 5 790 and 7 053,respectively. ·CONCLUSION:Both PRP combined with ranibizumab or TA for DME can effectively control disease progression in short time. Therapeutic effect is not significant between two methods, but PRP combined with TA is more economic.【期刊名称】《国际眼科杂志》【年(卷),期】2018(018)004【总页数】4页(P682-685)【关键词】糖尿病黄斑水肿;雷珠单抗;曲安奈德;玻璃体腔注射;全视网膜光凝【作者】潘竹娟;张志辉;樊飞红;郑晓柯;齐文娟【作者单位】510700 中国广东省广州市,广州医科大学附属第五医院眼科;510700 中国广东省广州市,广州医科大学附属第五医院眼科;510700 中国广东省广州市,广州医科大学附属第五医院眼科;510700 中国广东省广州市,广州医科大学附属第五医院眼科;510700 中国广东省广州市,广州医科大学附属第五医院眼科【正文语种】中文0引言糖尿病黄斑水肿(DME)是引起糖尿病患者视力下降的重要因素。

玻璃体内注射曲安奈德联合激光光凝治疗糖尿病性黄斑水肿的疗效

术前 视力 ( 1  ̄ .8 O0 O ) . O ,术后 1 个月矫正视力分别为 ( 2 + . ) ( 2 ± . ) 、3 O 2 O 5 和 O 9 O1 ,眼底 荧光血管造影 (F ) . 1 . 7 F A 及光学 相干断层扫描 (C ) 示 O T显 黄斑水肿明显消退 或减 轻 < . ) 0 1 O 。未见眼内感染 、视 网膜脱落 、 玻璃 体出血等并发症。 结论 : 玻璃体 内注射 曲安奈德联合 激光光凝治疗糖尿 病 f黄斑 水肿可以安全有效地提高视力 ,减轻黄斑水肿。 生
o ewe k a tr 1mlI n e fe VTA.o o e v e c r e t d v s a c i n c l r d ma i r v d b fr n fe e t n e T bs r e t o r c e i u la u t a d ma u a e h y e mp o e e o e a d a rt a me t1we k. 1 mo t n n h . t r n h a d 3 mo t s
Reut io s f ai tw r poe ralat e t n : h orc dvsa ci ee02 01) n (. O1)f r1 nh nh. s lVs n p tns eei rvdget f r ramet T e ret i l ut w r(. : i o e m y et c e u a y 2± . a d02 5 9± . a e mot,3mots 7t
5 一 00年 7 月 21 月确诊 为糖尿病性黄斑水 肿的 5 0例 ( 眼 ) 5 0 患者,采用 曲安奈德 4m 玻璃体 内注射,1 g 周后联 合黄斑部格栅 样光凝治疗。对
比观察治疗 前和治疗后 1 、1 周 个月及 3 个月最佳 矫正视力及黄斑水 肿的改善情况。 结果 : 选的 5 人 O例 ( 眼 ) 5 O 患者视力 均有不同程度提 高,

玻璃体腔注射雷珠单抗联合筋膜囊注射曲安奈德治疗视网膜静脉阻塞继发黄斑水肿

玻璃体腔注射雷珠单抗联合筋膜囊注射曲安奈德治疗视网膜静脉阻塞继发黄斑水肿李婷婷;牛彤彤【摘要】Objective To evaluate the clinial effect of intravitreal injection of ranibizumab combined with membrane sac injection of triamcinolone acetonide (TA) in the treatment of retinal vein occlusion (RVO) complicated with macular edema (ME). Methods There were 30 patients (30 eyes) who were diagnosed as RVO with macular edema by fundus fluorescence angiography (FFA) and optical coherence tomography (OCT). The changes of best corrected visual acuity (BCVA) and OCT were compared before and after the treatment by intravitreal injection of ranibizumab combined with membrane sac injection of TA. Results The BCVA before injection and after 1 week, 1 month, and 3 months of injection were (0.727±0.115),(0.591±0.062), (0.528±0.083), and (0.494±0.082). Central macular thickness (CMT) were (482.6±75.9) μm, (402.7±77.2)μm, (344.6±72.7)μm, and (310.6±68.7)μm respectively. BCVA was remarkably increased and CMT decreased after 1 month, 3 months, and 1 week of treatment, and the difference with those before treatment had statistical significance (P<0.05). Compared with those in 1 week after treatment BCVA increased and CMT decreased in 1 month and 3 months after treatment, and the difference had statistical significance (P<0.05). The difference between 1 month and 3 month after treatment of increased BCVA and decreased CMT had no statistical significance (P>0.05). Conclusion The treatment by intravitrealinjection of ranibizumab combined with membrane sac injection of TA can reduce macular edema in short time and increase BCVA. It provides a new idea for treating RVO complicated with macular edema, however, its long-term effect requires further observation.%目的:评价玻璃体腔注射雷珠单抗(ranibizumab)联合筋膜囊下注射曲安奈德(TA)治疗视网膜静脉阻塞(RVO)继发黄斑水肿(ME)的临床疗效。

  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

・62・ 中国实用医刊2015年1月第42卷第1期Chinese Journal of Practical Medicine Jan.2015,Vol。4互,No.1 内结核杆菌与纤维蛋白保护膜,防止潜在病灶传播。 从本次研究中可看出,注射激素的效果更好,安全 性更高,这种治疗方式值得临床推广应用。 参考文献 [1] 张晗.结核性腹膜炎102例临床分析[D].长春:吉林大学,2007. [2]薛萌.结核性腹膜炎106例临床分析[D].郑州:郑州大学,2012. [3] 黄晓玲.45例尿激酶腹腔内注射治疗结核性腹膜炎疗效分析[J]. 中国医学工程,2013,13(12):128.129. 

[4] [5] [6] 钟玲,肖嫒,卢水华.腹腔注射异烟肼和地塞米松治疗结核性腹膜 炎2O例[J].江汉大学学报:自然科学版,2006,34(2):76-77. 古丽那扎尔.108例结核性腹膜炎患者临床分析[D].乌鲁木齐: 新疆医科大学,2009. 冉秀丽.88例结核性腹膜炎的临床护理体会[J].求医问药(下半 月),2013,11(12):226. (收稿日期:2014—09—22) (本文编辑:王帆) 

雷珠单抗玻璃体腔内注射联合激光在糖尿病性 黄斑水肿中的应用 

潘敏敏 【摘要】 目的比较雷珠单抗玻璃体腔内注射联合激光和曲安奈德玻璃体腔内注射联合激光治疗糖尿病性 黄斑水肿的效果。方法将84例(90眼)糖尿病性黄斑水肿患者按照数字表法随机分为两组,观察组42例(44 眼)采用雷珠单抗玻璃体腔内注射联合激光治疗,对照组42例(46眼)采用曲安奈德玻璃体腔内注射联合激光治 疗。治疗后1、3、6、12个月对患者行视力、眼底、眼底荧光血管造影、黄斑区视网膜厚度检查。结果 观察组治疗 后1、3、6、12个月时显效率为70.5%、79.6%、76.2%、70.7%;对照组治疗后1、3、6、12个月时显效率为69.6%、 80.4%、69.4%、60.0%,两组治疗后1、3个月显效率比较差异无统计学意义(t=o.7246、0.3094,P>0.05),观察组 治疗后6、12个月显效率明显高于对照组(t=3.7068、5.7728,P<0.05)。观察组治疗后12个月视力变化较对照组 更明显(t=2.0962,P<0.05)。观察组治疗后6、12个月黄斑中心凹视网膜厚度变化比对照组更明显(t:5.7206, 3.6258,P<0.05)。结论在治疗糖尿病性黄斑水肿中,雷珠单抗玻璃体腔内注射联合激光远期效果优于曲安奈 德玻璃体腔内注射联合激光治疗。 【关键词】 黄斑水肿;雷珠单抗;激光 

Intravitreal injection of ranibizumab combined with laser in diabetic macular edema PA』V朋 一 min.Department of Ophthalmology,the Second Affiliated Hospital of Henan Science and Technology Uni— versity,Luoyang 47 1000,China 【Abstract】 Objective To compare the effect of intravitreal injection of ranibizumab combined with laser and intravitreal injection of triamcinolone acetonide combined with laser on diabetic macular e— dema.Methods Eighty-four cases(90 eyes)with diabetic macular edema were randomly divided into two groups according to figures.The observation group(42 cases,44 eyes)were operated through intravitreal in— jection of ranibizumab combined with laser and the control group(44 cases,46 eyes)were operated through intravitreal injection of triamcinolone acetonide combined with laser.To detect the visual acuity,fundus, fundus fluorescein angiography and macular thickness 1,3,6,12 months after treatment.Results 1,3,6, 12 months after treatment,the effective rates were 70.5%,79.6%,76.2%,70.7%in the observation group and 69.6%,80.4%,69.4%,60.O%in the control group.There were no significant difference be— tween the two groups 1,3months after treatment(t=0.7246,0.3094,P>0.05),the effective rates in the observation group were significantly higher than that in control group 6,12 month after treatment(t= 3.7068,5.7728,P<0.05).Twelve months after treatment,the vision changes in the observation group was significantly better than the control group(t=2.0962,P<0.05).And 6,12 months after the treat. ment,foveal retinal thickness changes in the observation group were improved significantly than that in the 

DOI:10.3760/cma.j.issn.1674—4756.2015.01.028 作者单位:471000洛阳,河南科技大学第二附属医院眼科 

control group(t=5.7206,3.6258,P<0.05). Conclusions In the treatment of diabetic 中国实用医刊2015年1月第42卷第1期Chinese Journal of Practical Medicine Jan.2015.Vo1.42.No.1 macular edema,long—term effect through intravitreal injection of ranibizumab combined with laser was im. proved significantly than intravitreal injection of triamcinolone acetonide combined with laser. 【Key words】 Macu]ar edema;Ranibizumab;Laser 

糖尿病性黄斑水肿(DME)是由于糖尿病导致的 视网膜微血管病变的一种,血管通透性增高导致细胞 外液渗漏和积聚,产生视网膜增厚或硬性渗出,严重影 响患者的视力。黄斑水肿目前在临床上还没有特效的 治疗方法,许多学者证实激光有效,但对一些距中心 凹<50 m或较严重的黄斑水肿,激光光凝受到限制, 有12%的患者单纯采用激光治疗无效,因为有水肿反 射激光能量或灼烧中心凹的风险的存在,更有一些报 告显示 ,单纯采用激光治疗会加重水肿。近年眼科 临床应用较多的是激光加用曲安奈德,具有显著的抗 炎作用,可以减轻黄斑水肿 。但也有研究显示,糖 皮质激素近期疗效显著,远期疗效有限,复发率较高。 因此,研究其他的治疗方法是临床研究的热点。近年 来,雷珠单抗是抗血管内皮生长因子(VEGF)药物,可 改善血管通透性,减轻黄斑水肿,已受到眼科工作者的 重视 J。本研究主要观察雷珠单抗玻璃体腔内注射 联合激光治疗糖尿病性黄斑水肿的疗效。 1资料与方法 1.1一般资料:选择2010年10月至2012年10月在 我院进行治疗的糖尿病性黄斑水肿患者84例(90眼) 为研究对象,均经眼底镜和眼底荧光血管造影(FFA) 证实,按照数字表法随机分为两组,观察组42例(44 眼),男23例,女19例,年龄41~73岁,平均(51.3± 5.7)岁,糖尿病病程5~27年,平均(13.1±3.6)年。 观察组42例(46眼),男2_5例,女l7例,年龄41~72 岁,平均(50.7±5.2)岁,糖尿病病程5~25年,平均 (12.8±3.4)年。排除标准:①禁忌行FFA检查者;② 既往曾患其他黄斑病变、老年性黄斑变性、中心性浆液 性视网膜病变;③近期内有糖皮质激素治疗者;④合并 有眼前节疾病;⑤合并有严重心、脑、肝、肾和造血系统 等疾病;⑥合并有恶性肿瘤者。两组患者性别、年龄、 病程、视力和黄斑区视网膜厚度等一般资料比较差异 无统计学意义(P>0.05),具有可比性。本研究经医 院医学伦理委员会批准,并与患者签署知情同意书。 1.2治疗方法:观察组采用玻璃体腔内注射雷珠单 抗:眼科手术要求常规消毒铺巾,眼表面采用爱尔卡因 麻醉后开睑,l ml空针抽取0.1 ml/0.3 mg的雷珠单 抗垂直于巩膜面在颞下方角膜缘后3.5 mm进针,将 药物缓慢注入玻璃体腔内,按压创口2~3 min,患眼常 规包扎。在第21天采用美国科医人公司ULI— MA2000SE型氪激光机行黄斑格栅样光凝,采用2~3 排,能量120~140 mV,距中心凹500 m向外,直径 

・63・ 100 m光斑,曝光时问0.2 S进行环形光凝,光斑反应 强度二级,中间间隔1个光斑直径。为避开视盘黄斑 束采用“C”形光凝。激光点数150点,一次完成。对 照组患者玻璃体腔内注射曲安奈德0.1 ml/4 mg,余治 疗同观察组。 1.3观察指标:治疗后1、3、6、12个月对患者行裸眼 视力、眼底、FFA检查,光学相干断层扫描(OCT)检测 黄斑区视网膜厚度。 1.4疗效判定标准 :显效:眼底检查出血吸收,黄 斑水肿消退,无灌注区消失,血管无渗漏。有效:出血 明显吸收,黄斑水肿明显减轻,无灌注区减少。无效: 病变未见明显减轻或加重。有效率=显效数/总数× 100%。 1.5统计学方法:统计学数据处理采用SPSS 10.0 统计分析软件。计数资料的比较采用秩和检验。计 量资料采用均数±标准差(x±s)表示,采用q检验 进行组内比较、组问比较,P<0.05为差异有统计学 意义。 2结果 2.1两组总疗效比较:观察组治疗后1、3、6、12个月 时显效率为70.5%、79.6%、76.2%、70.7%,对照组 分别为69.6%、80.4%、69.4%、60.0%。两组治疗后 1、3个月显效率比较差异无统计学意义(t=0.7246、 0.3094,P>0.05),观察组治疗后6、12个月显效率明 显高于对照组(t=3.7068、5.7728,P<0.05)。见 表1。 表1 两组糖尿病性黄斑水肿患者疗效比较(例) 

相关文档
最新文档